BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38223983)

  • 21. Characterization of transcriptomic signature of primary prostate cancer analogous to prostatic small cell neuroendocrine carcinoma.
    Alshalalfa M; Liu Y; Wyatt AW; Gibb EA; Tsai HK; Erho N; Lehrer J; Takhar M; Ramnarine VR; Collins CC; Den RB; Schaeffer EM; Davicioni E; Lotan TL; Bismar TA
    Int J Cancer; 2019 Dec; 145(12):3453-3461. PubMed ID: 31125117
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Neuroendocrine differentiation in adenocarcinoma of prostate during combined androgen blockade therapy: a case report].
    Kitamoto K; Hayashi T; Tamada S; Ezaki K; Kawashima H; Sugimura K; Nakatani T
    Hinyokika Kiyo; 2005 Jan; 51(1):33-5. PubMed ID: 15732339
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dual-Inhibitors of N-Myc and AURKA as Potential Therapy for Neuroendocrine Prostate Cancer.
    Ton AT; Singh K; Morin H; Ban F; Leblanc E; Lee J; Lallous N; Cherkasov A
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167327
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Neuroendocrine differentiation in adenocarcinoma of the prostate with progression of disease during hormonal treatment: a report of two cases].
    Kosugi M; Hanawa Y; Momma T; Saito S; Hirose S
    Nihon Hinyokika Gakkai Zasshi; 2003 May; 94(4):521-4. PubMed ID: 12795167
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Neuroendocrine differentiation in adenocarcinoma of the prostate during hormonal treatment: a case report].
    Matsumoto Y; Mibu H; Kagebayashi Y
    Hinyokika Kiyo; 2004 Nov; 50(11):813-5. PubMed ID: 15628545
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gene Expression Signature Predictive of Neuroendocrine Transformation in Prostate Adenocarcinoma.
    Ostano P; Mello-Grand M; Sesia D; Gregnanin I; Peraldo-Neia C; Guana F; Jachetti E; Farsetti A; Chiorino G
    Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32041153
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Role of Epigenetic Change in Therapy-Induced Neuroendocrine Prostate Cancer Lineage Plasticity.
    Storck WK; May AM; Westbrook TC; Duan Z; Morrissey C; Yates JA; Alumkal JJ
    Front Endocrinol (Lausanne); 2022; 13():926585. PubMed ID: 35909568
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Large cell neuroendocrine carcinoma of prostate: a clinicopathologic summary of 7 cases of a rare manifestation of advanced prostate cancer.
    Evans AJ; Humphrey PA; Belani J; van der Kwast TH; Srigley JR
    Am J Surg Pathol; 2006 Jun; 30(6):684-93. PubMed ID: 16723845
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma.
    Tsai HK; Lehrer J; Alshalalfa M; Erho N; Davicioni E; Lotan TL
    BMC Cancer; 2017 Nov; 17(1):759. PubMed ID: 29132337
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comprehensive serial molecular profiling of an "N of 1" exceptional non-responder with metastatic prostate cancer progressing to small cell carcinoma on treatment.
    Kadakia KC; Tomlins SA; Sanghvi SK; Cani AK; Omata K; Hovelson DH; Liu CJ; Cooney KA
    J Hematol Oncol; 2015 Oct; 8():109. PubMed ID: 26444865
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer.
    Puca L; Gavyert K; Sailer V; Conteduca V; Dardenne E; Sigouros M; Isse K; Kearney M; Vosoughi A; Fernandez L; Pan H; Motanagh S; Hess J; Donoghue AJ; Sboner A; Wang Y; Dittamore R; Rickman D; Nanus DM; Tagawa ST; Elemento O; Mosquera JM; Saunders L; Beltran H
    Sci Transl Med; 2019 Mar; 11(484):. PubMed ID: 30894499
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD44 expression is a feature of prostatic small cell carcinoma and distinguishes it from its mimickers.
    Simon RA; di Sant'Agnese PA; Huang LS; Xu H; Yao JL; Yang Q; Liang S; Liu J; Yu R; Cheng L; Oh WK; Palapattu GS; Wei J; Huang J
    Hum Pathol; 2009 Feb; 40(2):252-8. PubMed ID: 18835619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.
    Masumori N; Thomas TZ; Chaurand P; Case T; Paul M; Kasper S; Caprioli RM; Tsukamoto T; Shappell SB; Matusik RJ
    Cancer Res; 2001 Mar; 61(5):2239-49. PubMed ID: 11280793
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Neuroendocrine tumors of the prostate].
    Bours AF; Jorion JL; Donnay M; Ledent G; Van Ruyssevelt C
    Acta Urol Belg; 1993 Sep; 61(3):13-6. PubMed ID: 8256680
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuroendocrine cells of prostate cancer: biologic functions and molecular mechanisms.
    Huang YH; Zhang YQ; Huang JT
    Asian J Androl; 2019; 21(3):291-295. PubMed ID: 30924452
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Spatial Gene Expression Analysis Reveals Characteristic Gene Expression Patterns of De Novo Neuroendocrine Prostate Cancer Coexisting with Androgen Receptor Pathway Prostate Cancer.
    Watanabe R; Miura N; Kurata M; Kitazawa R; Kikugawa T; Saika T
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240308
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of intraductal carcinoma of the prostate detected by initial histological specimen and neuroendocrine prostate cancer: A report of three cases.
    Ikeda J; Ohe C; Ohsugi H; Matsuda T; Tsuta K; Kinoshita H
    Pathol Int; 2021 Sep; 71(9):621-626. PubMed ID: 34297443
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential expression of interleukin-8 and its receptors in the neuroendocrine and non-neuroendocrine compartments of prostate cancer.
    Huang J; Yao JL; Zhang L; Bourne PA; Quinn AM; di Sant'Agnese PA; Reeder JE
    Am J Pathol; 2005 Jun; 166(6):1807-15. PubMed ID: 15920165
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunohistochemical study of the neural development transcription factors (TTF1, ASCL1 and BRN2) in neuroendocrine prostate tumours.
    Rodríguez-Zarco E; Vallejo-Benítez A; Umbría-Jiménez S; Pereira-Gallardo S; Pabón-Carrasco S; Azueta A; González-Cámpora R; Espinal PS; García-Escudero A
    Actas Urol Esp; 2017 Oct; 41(8):529-534. PubMed ID: 28285791
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer.
    Brennen WN; Zhu Y; Coleman IM; Dalrymple SL; Antony L; Patel RA; Hanratty B; Chikarmane R; Meeker AK; Zheng SL; Hooper JE; Luo J; De Marzo AM; Corey E; Xu J; Yegnasubramanian S; Haffner MC; Nelson PS; Nelson WG; Isaacs WB; Isaacs JT
    JCI Insight; 2021 Apr; 6(8):. PubMed ID: 33724955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.